Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Astellas, Takeda to Lead Pack in FY2018 Japan Pharma Market: Citi Analyst
January 29, 2015
- Otsuka Establishes Marketing Base in Australia
January 29, 2015
- Astellas to Transfer Marketing Rights for 3 APIs to OrphanPacific
January 28, 2015
- PD-1, PD-L1 Inhibitors Could Carve Out 750 Billion Yen Market in Japan: Citi Analyst
January 28, 2015
- Takeda Launches Fomepizole
January 28, 2015
- Galderma Terminates Comarketing Agreement with Sato Pharmaceutical for Pekiron Cream
January 28, 2015
- Torii Files NDA for Sublingual Tablet for Mite Allergic Rhinitis
January 28, 2015
- Santen’s Dry Eye Treatment Receives Positive Opinion from CHMP
January 28, 2015
- Cost of Producing Antibody Drugs Remains High Despite Improvement in Culture Efficiency: Kyowa Kirin
January 27, 2015
- Xtandi Significantly Prolongs PFS in PII Study in Europe, US: Astellas
January 27, 2015
- Senshio Approved in Europe for Treatment of Symptomatic Vulvar, Vaginal Atrophy: Shionogi
January 26, 2015
- Takara Bio to Initiate Clinical Trial for Anticancer Agent HF10 in Japan
January 26, 2015
- US FDA Advisory Committee Recommends Approval of Astellas’s Azole Antifungal Agent
January 26, 2015
- Nihon Chouzai Confident of Continuing Early Price Settlements
January 23, 2015
- Open Tenders Good Example of Early Price Settlements: Qol Exec
January 22, 2015
- Lifestyle Disease-Related Medical Spending Must Be Pruned: Nobelpharma Pres.
January 22, 2015
- Medical System Network President Calls for Scrapping Fee Cut Rule
January 21, 2015
- Sakura Finetek Japan to Participate in Cervical Cancer Screening Project in Kazakhstan
January 21, 2015
- Meiji Seika Pharma Licenses Darinaparsin from Solasia Pharma in Japan
January 20, 2015
- Sanofi Launches Allegra Dry Syrup for Pediatric Patients Aged 6 Months and Older
January 20, 2015
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…